MedTrace Logo

Comparison of Pure Epicatechin and Cocoa on Markers of Vascular Function

NCT02221791 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-10-15

No results posted yet for this study

Summary

Intervention studies support a protective effect of flavonoid-rich foods such as chocolate and tea on cardiovascular disease risk. In a previous study we found that pure epicatechin improves markers of vascular function and insulin resistance although the results were less pronounced than the majority of chocolate intervention studies.

The food matrix of chocolate or other compounds present in chocolate could play a role in the bioavailability of flavonoids, resulting in these heightened improvements in vascular function.

In this study we aim to compare the acute effects of pure epicatechin and high-flavonoid chocolate on markers of vascular function.

Conditions

  • Endothelial Dysfunction
  • Bioavailability

Interventions

DIETARY_SUPPLEMENT

Pure Epicatechin

Participants will consume 100mg of epicatechin (capsule) + 70g white chocolate

DIETARY_SUPPLEMENT

High flavan-3-ol cocoa

Participants will consume 70g high flavan-3-ol cocoa (100mg epicatechin) + placebo capsule

DIETARY_SUPPLEMENT

Placebo

Participants will consume 70g white chocolate + placebo capsules

Sponsors & Collaborators

  • Top Institute Food and Nutrition

    collaborator OTHER

  • Wageningen University

    lead OTHER

Principal Investigators

  • Peter Hollman, Dr · Wageningen University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02221791 on ClinicalTrials.gov